About Dystroglycan 1
Dystroglycan 1 (DAG1) is a protein
from Homo sapiens identified by UniProt accession
Q14118, 895 residues long.
MolForge cross-references it against 0 known binders and
340 disease associations.
Target properties
| Protein name | Dystroglycan 1 |
|---|
| UniProt accession | Q14118 |
|---|
| Gene | DAG1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 895 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (340)
Diseases linked to this target (Open Targets).
- autosomal recessive limb-girdle muscular dystrophy type 2P · score 0.80
- muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A9 · score 0.74
- muscular dystrophy-dystroglycanopathy, type A · score 0.67
- limb-girdle muscular dystrophy · score 0.66
- qualitative or quantitative defects of alpha-dystroglycan · score 0.40
- congenital muscular dystrophy · score 0.37
- muscle-eye-brain disease with bilateral multicystic leucodystrophy · score 0.37
- Elevated circulating creatine kinase concentration · score 0.26
- isolated asymptomatic elevation of creatine phosphokinase · score 0.26
- breast adenocarcinoma · score 0.25
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q14118-F1 | alphafold | PREDICTED | 68.17 | — |
Amino-acid sequence (895 residues)
MRMSVGLSLL LPLSGRTFLL LLSVVMAQSH WPSEPSEAVR DWENQLEASM HSVLSDLHEA VPTVVGIPDG TAVVGRSFRV TIPTDLIASS GDIIKVSAAG KEALPSWLHW DSQSHTLEGL PLDTDKGVHY ISVSATRLGA NGSHIPQTSS VFSIEVYPED HSELQSVRTA SPDPGEVVSS ACAADEPVTV LTVILDADLT KMTPKQRIDL LHRMRSFSEV ELHNMKLVPV VNNRLFDMSA FMAGPGNAKK VVENGALLSW KLGCSLNQNS VPDIHGVEAP AREGAMSAQL GYPVVGWHIA NKKPPLPKRV RRQIHATPTP VTAIGPPTTA IQEPPSRIVP TPTSPAIAPP TETMAPPVRD PVPGKPTVTI RTRGAIIQTP TLGPIQPTRV SEAGTTVPGQ IRPTMTIPGY VEPTAVATPP TTTTKKPRVS TPKPATPSTD STTTTTRRPT KKPRTPRPVP RVTTKVSITR LETASPPTRI RTTTSGVPRG GEPNQRPELK NHIDRVDAWV GTYFEVKIPS DTFYDHEDTT TDKLKLTLKL REQQLVGEKS WVQFNSNSQL MYGLPDSSHV GKHEYFMHAT DKGGLSAVDA FEIHVHRRPQ GDRAPARFKA KFVGDPALVL NDIHKKIALV KKLAFAFGDR NCSTITLQNI TRGSIVVEWT NNTLPLEPCP KEQIAGLSRR IAEDDGKPRP AFSNALEPDF KATSITVTGS GSCRHLQFIP VVPPRRVPSE APPTEVPDRD PEKSSEDDVY LHTVIPAVVV AAILLIAGII AMICYRKKRK GKLTLEDQAT FIKKGVPIIF ADELDDSKPP PSSSMPLILQ EEKAPLPPPE YPNQSVPETT PLNQDTMGEY TPLRDEDPNA PPYQPPPPFT APMEGKGSRP KNMTPYRSPP PYVPP
Explore Dystroglycan 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets